Parsons R G, Hoch J A, Longmire R L
Cancer. 1978 Jun;41(6):2099-106. doi: 10.1002/1097-0142(197806)41:6<2099::aid-cncr2820410605>3.0.co;2-c.
Serial serum C3DP levels of 33 patients at our institution have been followed for up to 10 months. Individuals experiencing periods free of symptoms and signs of proliferating or expanding malignant disease, had C3DP levels which remained below 150 microgram/ml. Patients with active or recurrent disease, while on chemotherapy, had elevated C3DP values (greater than 150 microgram/ml). Serum C3DP values declined abruptly following treatment which resulted in major reduction of tumor mass. Decreases in C3DP levels from values above 150 microgram/ml to values within the normal range (50-150 microgram/ml) were observed during 89% (25/28) of the favorable clinical responses which have been followed with C3DP assays. Increases in C3DP levels from values within the normal range to values above 150 microgram/ml were observed either prior to or coordinate with clinical symptoms of disease recurrence 83% of the time (10/12 cases). These studies suggest that serial C3DP determinations offer an excellent prognostic aid for evaluating the response of malignant tumors during chemotherapeutic management.
我们机构对33例患者的血清C3DP水平进行了长达10个月的连续监测。经历无增殖或扩展恶性疾病症状和体征期的个体，其C3DP水平保持在150微克/毫升以下。患有活动性或复发性疾病且正在接受化疗的患者，其C3DP值升高（大于150微克/毫升）。治疗导致肿瘤肿块大幅缩小后，血清C3DP值急剧下降。在89%（25/28）经C3DP检测追踪的良好临床反应中，观察到C3DP水平从高于150微克/毫升降至正常范围（50 - 150微克/毫升）内。在83%的时间里（10/12例），在疾病复发的临床症状出现之前或与之同时，观察到C3DP水平从正常范围内的值升至高于150微克/毫升。这些研究表明，连续测定C3DP为评估化疗管理期间恶性肿瘤的反应提供了极好的预后辅助手段。
